PanDIA-1 is an ongoing prospective observational study for the early diagnosis of pancreatic cancer in high-risk individuals within the risk group of New Onset Diabetes type II (NOD).
Patients who are diagnosed with diabetes type II after the age of 50 years constitute a major risk group that suffer a 6-8 times increased risk of developing pancreatic cancer within 1-3 years.
By the end of 2017, Immunovia launched PanDIA-1 – the world’s most comprehensive prospective study for the early diagnosis of pancreatic cancer within the NOD risk group. The study was started in collaboration with Lund University, Uppsala University, Lund University’s Diabetes Center (LUDC), Region Skåne and Region Uppsala.
SWElife and DD2
A 7.6 million SEK grant from SWElife, the Swedish government’s strategic innovation program, was given to support this study. The SWElife program has supported the creation of one of the world’s largest biobank of recently diagnosed diabetes patients (21,000 diabetes patients from two Swedish regions via ANDIS (All New Diabetics in Skane) and ANDIU (All New Diabetics in Uppsala) studies. Through this collaboration, Immunovia can gain access up to 6,000 diabetic patients over 50 years of age for prospective tests using IMMray™ PanCan-d, over a period of three years.
The aim of PanDIA-1 is to validate the clinical utility of IMMray™ PanCan-d, proving the overall healthcare benefits and economics involved in testing for pancreatic cancer within the NOD risk group.
In January 2018, Immunovia also signed a letter of intent with the Danish Center for Strategic Research in Type 2 Diabetes (“DD2”), with the intention to include an additional 3,000 diabetes patients from Denmark for an extended PanDIA study.
Participants in the SWElife program and DD2 will be the two first participants in what is expected to become a global collaboration to examine the relationship between new onset diabetes type 2 in patients over 50 years of age and the risk of developing pancreatic cancer.
- Mikael Öman et al. ’Nationellt vårdprogram för pankreascancer och periampullär cancer’, Regionala cancercentrum i samverkan, 2012, s. 56.
- Damiano J, Bordier L, Le Berre JP, et al. ‘Should pancreas imaging be recommended in patients over 50 years when diabetes is discovered because of acute symptoms?’ Diabetes Metab 2004; 30: 203–07.
- Rahul Pannala, Ananda Basu, Gloria M Petersen et al. ‘New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer’, Lancet Oncol 2009; 10: 88–95, 2009., s. 89.